Until recently, the use of preventative immunotherapy in neuromyelitis optica spectrum disorders (NMOSD) was based on observational studies and clinical experiences. Meanwhile, the first drugs, among others the monoclonal antibody inebilizumab, were approved for the treatment of aquaporin-4 (AQP4) antibody-positive NMOSD. Inebilizumab binds to the CD19 antigen on B cells and leads to B-cell depletion. The first two dosages of 300 mg inebilizumab are administered intravenously at an interval of 2 weeks followed by further infusions every 6 months. In the placebo-controlled pivotal phase II/III study N-MOmentum, inebilizumab significantly prolonged the time to a first adjudicated relapse in AQP4 antibody-positive patients compared with placeb...
Michael Levy,1 Maureen A Mealy2 1Department of Neurology, Massachusetts General Hospital & Harvard M...
INTRODUCTION: Evidence-based treatment options for neuromyelitis optica spectrum disorders (NMOSD) p...
Neuromyelitis optica (NMO) is a severe inflammatory CNS disorder of putative autoimmune aetiology, w...
Abstract Background Treatment of neuromyelitis optica spectrum disorder (N...
INTRODUCTION: Treatment options for patients suffering from neuromyelitis optica spectrum disorders ...
Abstract Neuromyelitis optica (NMO) is a chronic inflammatory autoimmune disease of the central nerv...
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory ...
The first description of neuromyelitis optica by Eugène Devic and Fernand Gault dates back to the 19...
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system. C...
BackgroundInebilizumab is an anti-CD19 antibody approved for the treatment of neuromyelitis optica s...
This manuscript presents practical recommendations for managing acute attacks and implementing preve...
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that predominantly affects the o...
Neuromyelitis optica (NMO) is an autoimmune disease of the CNS that is characterized by inflammatory...
OBJECTIVE: To describe a patient with neuromyelitis optica (NMO) whose aquaporin 4 (AQP4) antibody l...
Background: Neuromyelitis optica (NMO) is a severe autoimmune disease targeting optic nerves and spi...
Michael Levy,1 Maureen A Mealy2 1Department of Neurology, Massachusetts General Hospital & Harvard M...
INTRODUCTION: Evidence-based treatment options for neuromyelitis optica spectrum disorders (NMOSD) p...
Neuromyelitis optica (NMO) is a severe inflammatory CNS disorder of putative autoimmune aetiology, w...
Abstract Background Treatment of neuromyelitis optica spectrum disorder (N...
INTRODUCTION: Treatment options for patients suffering from neuromyelitis optica spectrum disorders ...
Abstract Neuromyelitis optica (NMO) is a chronic inflammatory autoimmune disease of the central nerv...
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory ...
The first description of neuromyelitis optica by Eugène Devic and Fernand Gault dates back to the 19...
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system. C...
BackgroundInebilizumab is an anti-CD19 antibody approved for the treatment of neuromyelitis optica s...
This manuscript presents practical recommendations for managing acute attacks and implementing preve...
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that predominantly affects the o...
Neuromyelitis optica (NMO) is an autoimmune disease of the CNS that is characterized by inflammatory...
OBJECTIVE: To describe a patient with neuromyelitis optica (NMO) whose aquaporin 4 (AQP4) antibody l...
Background: Neuromyelitis optica (NMO) is a severe autoimmune disease targeting optic nerves and spi...
Michael Levy,1 Maureen A Mealy2 1Department of Neurology, Massachusetts General Hospital & Harvard M...
INTRODUCTION: Evidence-based treatment options for neuromyelitis optica spectrum disorders (NMOSD) p...
Neuromyelitis optica (NMO) is a severe inflammatory CNS disorder of putative autoimmune aetiology, w...